The team examined available scientific literature to determine the known biomarkers of influenza. Analysis revealed a number of volatile organic compounds and nitric oxide produced in parts of the lining of the human respiratory tract. The team then used nanotechnology — the manipulation of matter on a molecular level — created sensors to detect these specific gases in the breath of individuals infected with influenza.
The device could one day be widely distributed in drug stores, which would allow individuals to self-diagnose the virus early on and potentially seek medicinal intervention faster.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
“Before we applied nanotechnology to create this device, the only way to detect biomarkers in a person’s breath was through very expensive, highly-technical equipment in a lab, operated by skilled personnel,” said Perena Gouma, PhD, a professor in the materials science and engineering department at UTA and lead developer of the new technology. “I think that technology like this is going to revolutionize personalized diagnostics. This will allow people to be proactive and catch illnesses early, and the technology can easily be used to detect other diseases, such as Ebola virus disease, simply by changing the sensors.”
More articles on infection control:
Majority of Americans disagree with Trump’s vaccine views, survey finds
3 confirmed NTM infections in LA County
10 scabies cases reported at second Kettering Health hospital
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.